• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

家族性高胆固醇血症的遗传背景与诊断

Genetic backgrounds and diagnosis of familial hypercholesterolemia.

作者信息

Rogozik Joanna, Główczyńska Renata, Grabowski Marcin

机构信息

1st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.

出版信息

Clin Genet. 2024 Jan;105(1):3-12. doi: 10.1111/cge.14435. Epub 2023 Oct 17.

DOI:10.1111/cge.14435
PMID:37849044
Abstract

Lipid disorders play a critical role in the intricate development of atherosclerosis and its clinical consequences, such as coronary heart disease and stroke. These disorders are responsible for a significant number of deaths in many adult populations worldwide. Familial hypercholesterolemia (FH) is a genetic disorder that causes extremely high levels of LDL cholesterol. The most common mutations occur in genes responsible for low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB), or proprotein convertase subtilisin/kexin type 9 (PCSK9). While genetic testing is a dependable method for diagnosing the disease, it may not detect primary mutations in 20%-40% of FH cases.

摘要

脂质紊乱在动脉粥样硬化的复杂发展及其临床后果(如冠心病和中风)中起着关键作用。这些紊乱在全球许多成年人群中导致了大量死亡。家族性高胆固醇血症(FH)是一种导致低密度脂蛋白胆固醇水平极高的遗传性疾病。最常见的突变发生在负责低密度脂蛋白受体(LDLR)、载脂蛋白B(APOB)或前蛋白转化酶枯草杆菌蛋白酶/kexin 9型(PCSK9)的基因中。虽然基因检测是诊断该疾病的可靠方法,但在20%-40%的FH病例中可能无法检测到原发性突变。

相似文献

1
Genetic backgrounds and diagnosis of familial hypercholesterolemia.家族性高胆固醇血症的遗传背景与诊断
Clin Genet. 2024 Jan;105(1):3-12. doi: 10.1111/cge.14435. Epub 2023 Oct 17.
2
Molecular genetics of familial hypercholesterolemia in Israel-revisited.以色列家族性高胆固醇血症的分子遗传学研究回顾。
Atherosclerosis. 2017 Feb;257:55-63. doi: 10.1016/j.atherosclerosis.2016.12.021. Epub 2016 Dec 18.
3
Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.由前蛋白转化酶枯草杆菌蛋白酶/kexin 9型(PCSK9)功能获得性突变引起的纯合子家族性高胆固醇血症的基因型和表型特征。
Atherosclerosis. 2014 Sep;236(1):54-61. doi: 10.1016/j.atherosclerosis.2014.06.005. Epub 2014 Jun 26.
4
Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.德国家族性高胆固醇血症患者的临床特征及突变谱。
Atherosclerosis. 2016 Oct;253:88-93. doi: 10.1016/j.atherosclerosis.2016.08.037. Epub 2016 Aug 26.
5
Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.具有低密度脂蛋白受体(LDLR)突变的前蛋白转化酶枯草杆菌蛋白酶/kexin 9 V4I变体改变家族性高胆固醇血症的表型。
J Clin Lipidol. 2016 May-Jun;10(3):547-555.e5. doi: 10.1016/j.jacl.2015.12.024. Epub 2016 Jan 6.
6
Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town.开普敦家族性高胆固醇血症患者中的新型 PCSK9(前蛋白转化酶枯草溶菌素 9)变异体。
Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):934-943. doi: 10.1161/ATVBAHA.120.314482. Epub 2020 Nov 5.
7
Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship.西班牙的纯合子家族性高胆固醇血症:患病率及表型-基因型关系
Circ Cardiovasc Genet. 2016 Dec;9(6):504-510. doi: 10.1161/CIRCGENETICS.116.001545. Epub 2016 Oct 26.
8
Familial hypercholesterolemia with special focus on Japan.家族性高胆固醇血症,特别关注日本情况。
Clin Chim Acta. 2024 Mar 15;556:117847. doi: 10.1016/j.cca.2024.117847. Epub 2024 Feb 27.
9
Screening and verifying the mutations in the LDLR and APOB genes in a Chinese family with familial hypercholesterolemia.筛查并验证一个中国家族性高胆固醇血症家系中 LDLR 和 APOB 基因的突变。
Lipids Health Dis. 2023 Oct 18;22(1):175. doi: 10.1186/s12944-023-01935-8.
10
Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: A single center real-world study.家族性高胆固醇血症患者致病突变与 PCSK9 抑制剂治疗反应的相关性:一项单中心真实世界研究。
Nutr Metab Cardiovasc Dis. 2022 Mar;32(3):684-691. doi: 10.1016/j.numecd.2021.10.025. Epub 2021 Nov 11.

引用本文的文献

1
Integrative genetic analysis of shared genetic architecture of stroke and coronary artery disease: implications for pharmacist-led precision medicine.中风与冠状动脉疾病共享遗传结构的综合遗传分析:对药剂师主导的精准医学的启示。
Int J Clin Pharm. 2025 Jun 30. doi: 10.1007/s11096-025-01952-w.
2
Genetic Spectrum of Lithuanian Familial Hypercholesterolemia Patients.立陶宛家族性高胆固醇血症患者的基因谱
J Cardiovasc Dev Dis. 2025 May 21;12(5):197. doi: 10.3390/jcdd12050197.
3
Associations Between the Polymorphisms in the Coding Sequence of SLCO1B1 and Blood Lipid Levels Before and After Treatment by Atorvastatin in the Chinese Han Adults with Dyslipidemia.
中国汉族血脂异常成年人中SLCO1B1编码序列多态性与阿托伐他汀治疗前后血脂水平的关联
Pharmgenomics Pers Med. 2024 Dec 20;17:551-561. doi: 10.2147/PGPM.S482289. eCollection 2024.
4
Reduced circulating CD63 extracellular vesicle levels associate with atherosclerosis in hypercholesterolaemic mice and humans.循环 CD63 外泌体水平降低与高胆固醇血症小鼠和人类的动脉粥样硬化有关。
Cardiovasc Diabetol. 2024 Oct 17;23(1):368. doi: 10.1186/s12933-024-02459-w.
5
Gene Mutation in Patients with Familial Hypercholesterolemia and Response to Alirocumab Treatment-A Single-Centre Analysis.家族性高胆固醇血症患者的基因突变及对阿利西尤单抗治疗的反应——一项单中心分析
J Clin Med. 2024 Sep 22;13(18):5615. doi: 10.3390/jcm13185615.
6
Methylation status of , and is associated with cardiovascular events in familial hypercholesterolemia.、 和 的甲基化状态与家族性高胆固醇血症中的心血管事件相关。
Epigenomics. 2024;16(11-12):809-820. doi: 10.1080/17501911.2024.2351792. Epub 2024 Jun 17.
7
Impact of LDLR polymorphisms on lipid levels and atorvastatin's efficacy in a northern Chinese adult Han cohort with dyslipidemia.低密度脂蛋白受体基因多态性对中国北方成年汉族血脂异常人群血脂水平及阿托伐他汀疗效的影响
Lipids Health Dis. 2024 Apr 14;23(1):106. doi: 10.1186/s12944-024-02101-4.
8
ApoB100 and Atherosclerosis: What's New in the 21st Century?载脂蛋白B100与动脉粥样硬化:21世纪有哪些新进展?
Metabolites. 2024 Feb 12;14(2):123. doi: 10.3390/metabo14020123.